A Phase 3 interventional study of Deucravacitinib and Placebo in Juvenile Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Recruiting at 48 sites in 11 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Juvenile with a site in Brazil — 6 open to participants now, 9 under way, 5 of them phase 3. Arthritis, Juvenile · Brazil.
Among the 34 studies in Arthritis, Juvenile with a site in Brazil, this one is the 26th largest by planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2025, is one of 22 in phase 3, and was the 33rd registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →6 of the 34 studies in Arthritis, Juvenile with a site in Brazil are open now. Recruiting first, the newest first:
University of Sao Paulo General Hospital · Sites in Brazil
Ages 12–59 · Healthy volunteers
Janssen Research & Development, LLC · Sites in Brazil, United States, Argentina and 15 more countries
Ages 3+
AbbVie · Sites in Brazil, United States, Argentina and 14 more countries
Ages 1–17
University of Siena · Sites in Brazil, Algeria, Australia and 19 more countries
Eli Lilly and Company · Sites in Brazil, Argentina, Australia and 17 more countries
Ages 1–18
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 23 · Phase 4 4
First in 2000; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 181 across the 32 interventional studies, 2,150 across the 2 observational. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 34 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Arthritis, Juvenile with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Drug: Deucravacitinib
Drug: Deucravacitinib · Other: Placebo
Specified dose on specified days
Specified dose on specified days
Time to first flare during the withdrawal period
Time frame: From week 16 up to week 42
Trough concentration at steady state (Cminss)
Time frame: At week 16
Time-averaged steady-state concentration (Cavgss)
Time frame: At week 16
Steady-state maximum observed concentration (Cmaxss)
Time frame: At week 16
Number of participants with flare during the withdrawal period
Time frame: From week 16 up to week 42
Number of participants achieving low disease activity (Juvenile arthritis disease activity 71-joint score based on C-reactive protein (JADAS71-CRP) score: for oligoarthritis 1.1 to 2; for polyarthritis 1.1 to 3.8)
Time frame: Through week 16 and up to week 42
Number of participants achieving inactive disease (JADAS71-CRP score ≤ 1)
Time frame: Through week 16 and up to week 42
Number of participants attaining clinical remission for at least 6 consecutive months
Time frame: At week 42
Number of participants achieving psoriasis area and severity index (PASI) 75
Time frame: At week 42
Number of participants with adverse events (AEs)
Time frame: Up to week 42
Number of participants with adverse event of special interest (AESIs)
Time frame: Up to week 42
Number of participants with AEs leading to discontinuation
Time frame: Up to week 42
Number of participants with serious adverse events (SAEs)
Time frame: Up to week 42
Number of participants with Uveitis
Time frame: Up to week 42
Number of participants achieving each of juvenile idiopathic arthritis-American College of Rheumatology (JIA-ACR) (30/50/70/90)
Time frame: Through week 16 and up to week 42
Change from baseline in juvenile idiopathic arthritis-American College of Rheumatology (JIA-ACR) Core Criteria
Time frame: Through week 16 and up to week 42
Number of participants for each assessment who evaluate palatability scale as ≥ 3 (good or better), swallowability scale as ≤ 4 (neutral or easier), and taste scales (Sweetness, Bitterness, Flavor, and Overall Taste) as "None" or "Weak"
Time frame: At week 16
Assessment of exposure-response (E-R) utilizing steady-state exposure of deucravacitinib from the pharmacokinetic (PK) analysis and efficacy results using JIA-ACR 30
Time frame: At week 16
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Mar 2025 (actual). Primary completion is estimated for Mar 2030, 59 months after the start.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 59 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib